Art

J-GLOBAL ID：202102256197698845   Reference number：21A0026541

Mesenchymal stromal cell therapy for refractory graft-versus-host disease.

造血器腫瘍 造血幹細胞移植と細胞療法の展開 5)難治性GVHDに対する間葉系細胞療法

Author (2)： NAGAMURA TOKIKO (東大 医科研 病院 セルプロセッシング・輸血部/臍帯血・臍帯バンク/検査部) ,  TOJO ARINOBU (東大 医科研 病院 血液腫瘍内科)
Material： 月刊腫瘍内科  (腫瘍内科)
Volume： 26  Issue： 6  Page： 671-676  Publication year： Dec. 28, 2020 
JST Material Number： L6395A  ISSN： 1881-6568  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *間葉系細胞療法 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0026541&from=J-GLOBAL&jstjournalNo=L6395A") }}

JST classification (3)： Treatment for immunologic diseases,allergic diseases.  (GD04030Y) ,  Blood cell tumors(=neoplasms)  (GK04000M) ,  Treatment for tumors in general  (GE03031L)

Reference (28)：

• Nagamura-Inoue T, Nagamura F. Umbilical Cord Blood and Cord Tissue Bank as a Source for Allogeneic Use. IntechOpen. 2020 ; Chapter : 1-25.
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006 ; 8 : 315.
• Krampera M, Galipeau J, Shi Y, et al. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013 ; 15 : 1054.
• Guan Q, Li Y, Shpiruk T, et al. Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells. Cytotherapy. 2018.
• Muñoz J, Akhavan NS, Mullins AP, Arjmandi BH. Macrophage Polarization and Osteoporosis : A Review. Nutrients 2020 ; 12 : E2999.

Terms in the title (7)： 造血器腫瘍 ,  造血幹細胞移植 ,  細胞療法 ,  展開 ,  GVHD ,  間葉系細胞 ,  療法